Kenvue Inc. (KVUE)vs22nd Century Group Inc (XXII)
KVUE
Kenvue Inc.
$17.53
+1.74%
CONSUMER DEFENSIVE · Cap: $33.58B
XXII
22nd Century Group Inc
$1.56
-3.11%
CONSUMER DEFENSIVE · Cap: $1.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Kenvue Inc. generates 214455% more annual revenue ($15.12B vs $7.05M). KVUE leads profitability with a 9.7% profit margin vs -71.7%. KVUE earns a higher WallStSmart Score of 58/100 (C).
KVUE
Buy58
out of 100
Grade: C
XXII
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.9%
Fair Value
$16.00
Current Price
$17.53
$1.53 premium
Margin of Safety
+70.6%
Fair Value
$19.09
Current Price
$1.56
$17.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
3.2% revenue growth
Weak financial health signals
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -116.6% — below average capital efficiency
Revenue declined 43.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : KVUE
PEG of 1.48 suggests the stock is reasonably priced for its growth.
Bull Case : XXII
The strongest argument for XXII centers on Price/Book.
Bear Case : KVUE
The primary concerns for KVUE are Revenue Growth, Piotroski F-Score, Altman Z-Score.
Bear Case : XXII
The primary concerns for XXII are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
KVUE profiles as a value stock while XXII is a turnaround play — different risk/reward profiles.
XXII carries more volatility with a beta of 1.12 — expect wider price swings.
KVUE is growing revenue faster at 3.2% — sustainability is the question.
KVUE generates stronger free cash flow (744M), providing more financial flexibility.
Bottom Line
KVUE scores higher overall (58/100 vs 31/100). XXII offers better value entry with a 70.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kenvue Inc.
CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA
Kenvue Inc. is a consumer health company globally.
Visit Website →22nd Century Group Inc
CONSUMER DEFENSIVE · TOBACCO · USA
22nd Century Group Inc (Ticker: XXII) is an innovative biopharmaceutical and agricultural company dedicated to tobacco harm reduction through advanced genetic engineering techniques. By focusing on the development of low-nicotine tobacco products, the firm aims to mitigate nicotine addiction while enhancing public health outcomes. As it strategically diversifies into the burgeoning hemp and cannabis markets, 22nd Century positions itself to capitalize on the expanding legal cannabis landscape. With a robust commitment to scientific research and adherence to regulatory frameworks, the company represents a compelling investment opportunity for institutional investors looking to engage in transformative sectors.
Compare with Other HOUSEHOLD & PERSONAL PRODUCTS Stocks
Want to dig deeper into these stocks?